Korsana Biosciences
Latest round
- Series A
Last raised
- Feb 2025
Total raised
- $175M
Investors
- 8
About Korsana Biosciences
Founded in 2024, Korsana Biosciences operates from Waltham, US. The company specializes in developing therapeutics for neurodegenerative disorders. The founder has previously established other ventures, though specific details are not disclosed.Korsana Biosciences is focused on developing innovative therapeutics aimed at addressing neurodegenerative diseases, with a primary emphasis on Alzheimer's disease. Their core product, KRSA-028, is a next-generation shuttled monoclonal antibody specifically designed to target amyloid beta, a protein implicated in the pathogenesis of Alzheimer's. This therapeutic is delivered using Korsana's proprietary Therapeutic Targeting (THETA™) platform, which enhances the delivery of large molecules across the blood-brain barrier, thereby improving central nervous system (CNS) exposure. The end users of these products include patients suffering from Alzheimer's, along with caregivers and healthcare providers who are seeking effective treatment options.Korsana Biosciences generates revenue through strategic partnerships and collaborations in the biotechnology sector. The company collaborates with Paragon Therapeutics to leverage their THETA™ platform in a manner that enhances the efficacy of their investigational therapies. Transactions typically involve licensing agreements and milestone payments contingent upon the achievement of specific clinical development goals. The financial structure may also include upfront payments associated with partnerships, along with ongoing royalties from product sales once they receive regulatory approval. This financial backing is intended to facilitate the development of upcoming products targeting various neurodegenerative conditions and to explore expansion into additional markets in North America and Europe.
Who invested in Korsana Biosciences
8 investors across 2 rounds
See all investors in Korsana Biosciences
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Korsana Biosciences
Who invested in Korsana Biosciences?
Korsana Biosciences has 8 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Korsana Biosciences raised?
Korsana Biosciences has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Korsana Biosciences last raise money?
Korsana Biosciences's most recent round on record is a Series A, in Feb 2025.
What does Korsana Biosciences do?
Founded in 2024, Korsana Biosciences operates from Waltham, US.
Where is Korsana Biosciences headquartered?
Korsana Biosciences is headquartered in Waltham, US.
Which VCs invest in companies like Korsana Biosciences?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Korsana Biosciences's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Korsana Biosciences? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.